A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
Sponsored by GlaxoSmithKline
About this trial
Last updated 8 years ago
Study ID
114812
Status
Completed
Type
Observational
Placebo
No
Accepting
All
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 16 years ago
What is this trial about?
Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both
ocular and nasal symptoms have a greater burden of illness and lower quality of life than
patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both
nasal and ocular symptoms. The purpose of this study was to evaluate the differences in
symptom control (both perceptually and objectively) and resource use for patients with
current seasonal AR.
What are the Participation Requirements?
Patient Inclusion Criteria:
- Current Seasonal Allergic Rhinitis sufferer (based on physician judgement)
- Currently receiving prescribed INS treatment (no other treatment restrictions apply)
- Have consumed at least one full prescription on the specified INS treatment
- No comorbid Asthma or COPD diagnosis
- Informed Consent
Exclusion Criteria:
- None specified